Abstract TH834: Novel Pharmacist-Led Shared Care Program Improved Lipid Control In Stable Ischemic Heart Disease Patients.

Abstract

Introduction: The Ischemic Heart Disease (IHD) Shared Care programme (SC) was conceptualised to facilitate the joint management of patients with stable ischemic heart disease between the cardiac specialist and primary care providers with a focus on aggressive secondary cardiovascular risk reduction. During the first year, patients under the SC programme were reviewed by clinical pharmacists in primary care every 4 months with an annual review by the primary cardiologist. Aims: We aimed to evaluate the cardiovascular risk factor control (CVRF) of IHD patients under SC as compared with patients under standard care. Methodology: A retrospective analysis of patients enrolled under SC from 1 st July 2024 to 31 st March 2025 was conducted with events monitored until 1 st October 2025. Participants in SC were compared with other IHD patients undergoing standard care. The primary outcome was control of cardiovascular risk factors. Results: Figure 1 outlines the SC model compared with standard care. A total of 51 patients under the Shared Care programme and 433 patients in the standard care were analysed in the study. Table 1 describes the characteristics of the study populations. Patient in both groups were similarly matched in age, gender, previous acute coronary syndromes and cardiovascular risk factors. Table 2 depicts the CVRF control and safety signals at follow-up. Patients under SC had a significantly lower LDL level (1.55 ± 0.357 mmol/L vs 1.90 ± 0.810mmol/L, p= 0.003) with similar HbA1c levels and blood pressure control. Patients in SC had a higher visit frequency (2.94 ± 1.54 vs 1.05 ± 1.28, p < 0.001). No increase in safety signals of unplanned specialist clinic review or hospitalisation were observed. Conclusion: Patients under pharmacy-led shared care programme had better management lipid management compared with standard care with no safety signals observed.